TradeUP Acquisition Corp. Warrant (ESLAW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
TradeUP Acquisition Corp. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 33,982 | $1,760 | $4,417.66 | $2,657.66 | 151% |
TradeUP Acquisition Corp. Warrant (ESLAW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has TradeUP Acquisition Corp. Warrant ever had a stock split?
TradeUP Acquisition Corp. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Cheng Liu CEO | NASDAQ (CM) Exchange | 297584112 CUSIP |
| US Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company situated in Emeryville, California, USA, focusing on the development of innovative T-cell therapies aimed at treating various forms of blood cancers and solid tumors. With a dedicated approach to immunotherapy, Estrella Immunopharma is at the forefront of utilizing genetically engineered T-cells to target and eliminate cancer cells. Their strategic partnership with Imugene Limited highlights their commitment to expanding therapy options for solid tumors, leveraging the potential of combined expertise and resources in the fight against cancer.
Products and Services
- EB103
As the lead product candidate in Estrella Immunopharma’s pipeline, EB103 is designed to combat diffuse large B-cell lymphoma (DLBCL), which is a common and aggressive form of non-Hodgkin lymphoma. This therapy is currently undergoing preclinical trials, focusing on its efficiency and safety as a promising treatment for patients with this challenging condition.
- EB104
Another key product candidate from Estrella Immunopharma, EB104, targets not only diffuse large B-cell lymphoma but also acute lymphocytic leukemia (ALL), a type of cancer of the blood and bone marrow that affects white blood cells. EB104 is being developed to offer a novel therapeutic option for patients suffering from these types of cancer, demonstrating Estrella Immunopharma’s commitment to addressing a broad range of hematological malignancies.
- Collaboration with Imugene Limited
This collaborative partnership aims to advance the treatment of solid tumors through the development of a specialized therapy that combines Imugene's CF33-CD19t oncolytic virus with Estrella Immunopharma's EB103. The synergy between these two innovative approaches holds the potential to enhance therapeutic efficacy against solid tumors, showcasing a forward-thinking strategy to tackle challenging cancer types.
